Eton Pharmaceuticals Inc
Eton Pharmaceuticals Inc (ETON) Historical Volatility
ETON's 30 day historical volatility is 82.05%, in the 87th percentile of readings over the past year. This is a high percentile, meaning Eton Pharmaceuticals Inc shares have swung far more than usual. ETON's 30 day implied volatility sits at 65.11%, with an IV Rank of 13.49%, leaving IV 16.94 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking ETON historical volatility helps you see how much Eton Pharmaceuticals Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ETON's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ETON 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ETON's 30 day historical volatility, or ETON HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ETON's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →